{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T01:47:05Z","timestamp":1791424025994,"version":"4.3.3"},"reference-count":58,"publisher":"BMJ","issue":"8","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Gut"],"accepted":{"date-parts":[[2014,9,18]]},"published-print":{"date-parts":[[2015,8]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>A new scenario of therapy for chronic hepatitis C (CHC) is being established with the approval of sofosbuvir (SOF).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To estimate the cost-effectiveness of SOF-based regimens approved in the Summary of Product Characteristics (SmPC) versus the standard of care for different genotypes and patient populations (naive or pretreated).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A Markov model simulating CHC progression was used to estimate disease treatment costs and effects over patients\u2019 lifetimes, from the Spanish National Public Healthcare System perspective. Different therapeutic options were analysed for genotypes 1, 2 and 3 in naive population and for genotype 2 and 3 pretreated patients, according to data obtained from clinical trials. A one-way sensitivity analysis was performed to evaluate the uncertainty of certain parameters: treatment starting age, transition probabilities, drug costs and discount rate. A probabilistic sensitivity analysis was also carried out.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>For the naive population, the option SOF+pegylated-interferon-\u03b1 (pIFN)+ribavirin (RBV) for 12\u2005weeks recorded in SmPC for genotype 1 and 3 versus pIFN+RBV for 24\u2005weeks estimated an incremental cost-effectiveness ratio (ICER) below the \u20ac40\u2005000\/quality-adjusted life-year (QALY) benchmark. For the pretreated population, SOF triple therapy reached an ICER on the threshold limit for genotype 3. Other options included in SmPC for different genotypes exceeded the accepted efficiency limit in our setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The options that included SOF+RBV+pIFN in a 12-week course regimen fell below the efficiency threshold considered in our setting. IFN-free regimens administered for 24\u2005weeks reached figures over the benchmark of \u20ac40\u2005000\/QALY.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/gutjnl-2014-307772","type":"journal-article","created":{"date-parts":[[2014,10,14]],"date-time":"2014-10-14T03:05:05Z","timestamp":1413255905000},"page":"1277-1288","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":45,"title":["Cost-effectiveness analysis of sofosbuvir-based regimens for chronic hepatitis C"],"prefix":"10.1136","volume":"64","author":[{"given":"Ram\u00f3n","family":"San Miguel","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Complejo Hospitalario de Navarra, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicente","family":"Gimeno-Ballester","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Hospital Universitario Miguel Servet, Zaragoza, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Bl\u00e1zquez","sequence":"additional","affiliation":[{"name":"Department of Medicines for Human Use, Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Mar","sequence":"additional","affiliation":[{"name":"Clinical Management Service, Hospital Alto Deba, Mondragon, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2014,10,13]]},"reference":[{"key":"2025121222233468000_64.8.1277.1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2011.02703.x"},{"key":"2025121222233468000_64.8.1277.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199908193410802"},{"key":"2025121222233468000_64.8.1277.3","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24641"},{"key":"2025121222233468000_64.8.1277.4","doi-asserted-by":"publisher","DOI":"10.1001\/jama.280.24.2088"},{"key":"2025121222233468000_64.8.1277.5","unstructured":"van de Laar M , Veldhuijzen I , Hahn S . Hepatitis B and C in the EU neighbourhood: prevalence, burden of disease and screening policies. Stockholm: European Centre for Disease Prevention and Control, 2010:56."},{"key":"2025121222233468000_64.8.1277.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1010494"},{"key":"2025121222233468000_64.8.1277.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1012912"},{"key":"2025121222233468000_64.8.1277.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009482"},{"key":"2025121222233468000_64.8.1277.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1013086"},{"key":"2025121222233468000_64.8.1277.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1214854"},{"key":"2025121222233468000_64.8.1277.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1214853"},{"key":"2025121222233468000_64.8.1277.12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60247-0"},{"key":"2025121222233468000_64.8.1277.13","doi-asserted-by":"publisher","DOI":"10.1586\/14737167.2014.906307"},{"key":"2025121222233468000_64.8.1277.14","doi-asserted-by":"crossref","unstructured":"Gold M , Siegel J , Russell L , eds. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996.","DOI":"10.1093\/oso\/9780195108248.001.0001"},{"key":"2025121222233468000_64.8.1277.15","unstructured":"Drummond MF , O'Brien B , Stoddart GL , et al . Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press, 2003."},{"key":"2025121222233468000_64.8.1277.16","unstructured":"European Medicines Agency. Sovaldi product information. 2014. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002798\/WC500160597.pdf (accessed 3 May 2014)."},{"key":"2025121222233468000_64.8.1277.17","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/S0213-9111(02)71933-X","article-title":"\u00bfQu\u00e9 es una tecnolog\u00eda sanitaria eficiente en Espa\u00f1a?","volume":"4","author":"Sacristan","year":"2002","journal-title":"Gac Sanit"},{"key":"2025121222233468000_64.8.1277.18","doi-asserted-by":"crossref","unstructured":"Lalezari JP , Nelson DR , Hyland RH , et al . Once-Daily Sofosbuvir Plus Ribavirin Given for 12 or 24 Weeks in Treatment-Na\u00efve Patients With HCV Infection: the QUANTUM Study. 48th Annual Meeting of the European Association for the Study of the Liver, 24\u201328 April 2013, Amsterdam, The Netherlands. 2013.","DOI":"10.1016\/S0168-8278(13)60847-8"},{"key":"2025121222233468000_64.8.1277.19","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.109309"},{"key":"2025121222233468000_64.8.1277.20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020047"},{"key":"2025121222233468000_64.8.1277.21","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1016\/S0168-8278(13)60016-1","article-title":"All-oral sofosbuvir-based 12-week regimens for the treatment of chronic HCV infection: the ELECTRON study","volume":"58","author":"Gane","year":"2013","journal-title":"J Hepatol"},{"key":"2025121222233468000_64.8.1277.22","doi-asserted-by":"crossref","first-page":"s28","DOI":"10.1016\/S0168-8278(11)60063-9","article-title":"Once daily PSI 7977 PegIFN\/RBV in a phase 2b trial: rapid virologic suppression in treatment-naive patients with G2\/G3","volume":"54","author":"Lalezari","year":"2011","journal-title":"J Hepatol"},{"key":"2025121222233468000_64.8.1277.23","first-page":"733A","article-title":"Sofosbuvir+ribavirin for 12 or 24 weeks for patients with HCV genotype 2 or 3: the VALENCE trial [abstract no. 1085]","volume":"58","author":"Zeuzem","year":"2013","journal-title":"Hepatology"},{"key":"2025121222233468000_64.8.1277.24","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.01.039"},{"key":"2025121222233468000_64.8.1277.25","first-page":"1380A","article-title":"Sofosbuvir in combination with PegIFN and ribavirin for 12 weeks provides high SVR rates in HCV-infected genotype 2 or 3 treatment experienced patients with and without compensated cirrhosis: results from the LONESTAR-2 study","volume":"58","author":"Lawitz","year":"2013","journal-title":"Hepatology"},{"key":"2025121222233468000_64.8.1277.26","unstructured":"Osakidetza. Comit\u00e9 de evaluaci\u00f3n de nuevos medicamentos de uso Hospitalario: Telaprevir (Incivo\u00ae). http:\/\/www.osakidetza.euskadi.net\/r85-pkcevi03\/es\/contenidos\/informacion\/cevime_ambito_hospitalario\/es_cevime\/adjuntos\/telaprevir_informe.pdf (accessed 1 Apr 2014)."},{"key":"2025121222233468000_64.8.1277.27","unstructured":"Osakidetza. Comit\u00e9 de evaluaci\u00f3n de nuevos medicamentos de uso Hospitalario: Boceprevir (Victrelis \u00ae). http:\/\/www.osakidetza.euskadi.net\/r85-pkcevi03\/eu\/contenidos\/informacion\/cevime_ambito_hospitalario\/eu_miez\/adjuntos\/boceprevir_informe.pdf (accessed 1 Apr 2014)."},{"key":"2025121222233468000_64.8.1277.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2011.06.006"},{"key":"2025121222233468000_64.8.1277.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2009.12.028"},{"key":"2025121222233468000_64.8.1277.30","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-147-10-200711200-00003"},{"key":"2025121222233468000_64.8.1277.31","doi-asserted-by":"publisher","DOI":"10.1053\/gast.1997.v112.pm9024300"},{"key":"2025121222233468000_64.8.1277.32","first-page":"161","article-title":"Cost effectiveness of the treatment of chronic hepatitis C with interferon-alpha","volume":"21","author":"Buti","year":"1998","journal-title":"Gastroenterol Hepatol"},{"key":"2025121222233468000_64.8.1277.33","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200523100-00007"},{"key":"2025121222233468000_64.8.1277.34","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2003.01494.x"},{"key":"2025121222233468000_64.8.1277.35","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-013-0080-3"},{"key":"2025121222233468000_64.8.1277.36","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2005.064774"},{"key":"2025121222233468000_64.8.1277.37","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2013.860033"},{"key":"2025121222233468000_64.8.1277.38","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2013.844159"},{"key":"2025121222233468000_64.8.1277.39","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-005-0280-7"},{"key":"2025121222233468000_64.8.1277.40","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X9301300409"},{"key":"2025121222233468000_64.8.1277.41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2004.01.005"},{"key":"2025121222233468000_64.8.1277.42","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwf100"},{"key":"2025121222233468000_64.8.1277.43","unstructured":"Organizaci\u00f3n Nacional de Transplantes. Registro espa\u00f1ol de transplante hep\u00e1tico. Memoria de resultados, 2010. http:\/\/www.ont.es\/infesp\/Registros\/MEMORIA%20RETH%202010.pdf (accessed 1 Apr 2014)."},{"key":"2025121222233468000_64.8.1277.44","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-127-10-199711150-00001"},{"key":"2025121222233468000_64.8.1277.45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2013.05.019"},{"key":"2025121222233468000_64.8.1277.46","doi-asserted-by":"publisher","DOI":"10.1002\/hep.25734"},{"key":"2025121222233468000_64.8.1277.47","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2013.05.014"},{"key":"2025121222233468000_64.8.1277.48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2013.07.006"},{"key":"2025121222233468000_64.8.1277.49","doi-asserted-by":"crossref","unstructured":"Briggs AH , Claxton K , Sculpher MJ . Decision modelling for health economic evaluation. Oxford university press, 2006.","DOI":"10.1093\/oso\/9780198526629.001.0001"},{"key":"2025121222233468000_64.8.1277.50","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-199402000-00006"},{"key":"2025121222233468000_64.8.1277.51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta10210","article-title":"Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation","volume":"10","author":"Wright","year":"2006","journal-title":"Health Technol Assess"},{"key":"2025121222233468000_64.8.1277.52","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X0202200408"},{"key":"2025121222233468000_64.8.1277.53","unstructured":"National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal. http:\/\/www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/191504\/NICE_guide_to_the_methods_of_technology_appraisal.pdf (accessed 15 Jul 2014)."},{"key":"2025121222233468000_64.8.1277.54","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2013.02.002"},{"key":"2025121222233468000_64.8.1277.55","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.03.011"},{"key":"2025121222233468000_64.8.1277.56","unstructured":"Tice JA , Ollendorf DA , Pearson SD . The Comparative Clinical Effectiveness and Value of Simeprevir and Sofosbuvir in the Treatment of Chronic Hepatitis C Infection. 2014. http:\/\/www.ctaf.org\/sites\/default\/files\/assessments\/CTAF_Hep_C_Apr14_final.pdf (accessed 3 May 2014)."},{"key":"2025121222233468000_64.8.1277.57","unstructured":"The Editorial Board. How Much Should Hepatitis C Treatment Cost? The New York Times. 2014. http:\/\/www.nytimes.com\/2014\/03\/16\/opinion\/sunday\/how-much-should-hepatitis-c-treatment-cost.html (accessed 3 May 2014)."},{"key":"2025121222233468000_64.8.1277.58","unstructured":"Drugs for Hepatitis C. The New York Times. 2014. http:\/\/www.nytimes.com\/2014\/03\/26\/opinion\/drugs-for-hepatitis-c.html (accessed 3 May 2014)."}],"container-title":["Gut"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/gutjnl-2014-307772","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T06:23:43Z","timestamp":1765607023000},"score":1,"resource":{"primary":{"URL":"https:\/\/gut.bmj.com\/lookup\/doi\/10.1136\/gutjnl-2014-307772"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10,13]]},"references-count":58,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2015,7,9]]},"published-print":{"date-parts":[[2015,8]]}},"alternative-id":["10.1136\/gutjnl-2014-307772"],"URL":"https:\/\/doi.org\/10.1136\/gutjnl-2014-307772","relation":{},"ISSN":["0017-5749","1468-3288"],"issn-type":[{"value":"0017-5749","type":"print"},{"value":"1468-3288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10,13]]}}}